EXHIBIT 23.1

                         CONSENT OF INDEPENDENT AUDITORS



The Board of Directors
Northwest Biotherapeutics, Inc.:


We consent to the use of our report dated April 17, 2001, except as to notes
4(b) and 5(d), which are as of May 15, 2001, relating to the consolidated
balance sheets of Northwest Biotherapeutics, Inc. (a development stage company)
and subsidiary (Company) as of December 31, 1999 and 2000 and the related
consolidated statements of operations, stockholders' deficit and comprehensive
loss, and cash flows for each of the years in the three-year period ended
December 31, 2000 and the period from March 18, 1996 (inception) through
December 31, 2000 included herein, and to the reference to our firm under the
heading "Experts" in the prospectus.

Our report dated April 17, 2001, except as to notes 4(b) and 5(d), which are as
of May 15, 2001, contains an explanatory paragraph that states that the Company
has incurred losses from operations, has a net capital deficiency and, at
December 31, 2000, a net working capital deficit that raise substantial doubt
about its ability to continue as a going concern. The consolidated financial
statements do not include any adjustments that might result from the outcome of
this uncertainty.



/s/ KPMG LLP

Seattle, Washington

November 14, 2001